Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Contrast Enhanced EUS for Pancreas Lesions
NCT04324294Phase 1Recruiting
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Feb 2020
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sulfur hexafluoride in pancreatic cancer (PC), pancreatitis and pancreatic cyst, sponsored by Cedars-Sinai Medical Center. Primary endpoint: Diagnostic yield of EUS versus contrast EUS at 12 months. Started Feb 2020; status: recruiting.
02
Drugs
sulfur hexafluoride
03
Conditions
pancreatic cancer (PC)pancreatitispancreatic cyst
Beyond the preview
Go deeper on NCT04324294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04324294.